The Effects of Losartan on Reward Reinforcement Learning
The Role of the Renin-angiotensin System in Reward Reinforcement Learning
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 611731
- Rekruttering
- University of Electronic Science and Technology of China
-
Kontakt:
- Weihua Zhao, PhD
- E-mail: zarazhao.uestc@outlook.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy subjects without past or current psychiatric or neurological disorders
- Right-handedness
- Normal or corrected-normal version
Exclusion Criteria:
- History of head injury
- Medical or psychiatric illness
- Hypertension
- General cardio-vascular alteration or diseases
- Allergy against medications
- Visual or motor impairments
- Claustrophobia
- Drug addiction
- Nicotine dependence
- FMRI contradictions
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Losartan gruppe
Lægemiddel: Losartan
|
administration of losartan (50 mg) (oral)
Andre navne:
|
|
Placebo komparator: Placebo gruppe
Lægemiddel: Placebo oral tablet
|
administration of placebo (oral)
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
BOLD-level activity as assessed by fMRI during the learning phase
Tidsramme: 90 minutes to 110 minutes after treatment
|
During the paradigm subjects will learn the reward properties of stimuli via the presentation of trial-wise feedback.
The neural activation during the prediction of positive and negative outcome feedback will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions.
The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.
|
90 minutes to 110 minutes after treatment
|
|
BOLD-level activity as assessed by fMRI during the learning transfer phase
Tidsramme: 111 minutes to 120 minutes after treatment
|
Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities.
The neural activation during correct responses will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions.
The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.
|
111 minutes to 120 minutes after treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Choice accuracy for the stimulus with the high reward probability during the learning phase
Tidsramme: 90 minutes to 110 minutes after treatment
|
During the learning phase accuracies (in percent) for choosing the stimulus with the highest reward probability will be computed.
Effects of treatment on choice accuracy in the probabilistic learning task will be examined by comparing accuracies (percent) between the losartan- and placebo-treated group.
|
90 minutes to 110 minutes after treatment
|
|
Learning rate for positive and negative outcomes
Tidsramme: 90 minutes to 110 minutes after treatment
|
The learning rate will be determined by performing computational modelling.
The learning rate index for positive and negative outcomes during the learning phase will be compared between the losartan- and placebo-treated group.
|
90 minutes to 110 minutes after treatment
|
|
Choice accuracy during the learning transfer phase
Tidsramme: 111 minutes to 120 minutes after treatment
|
Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities.
For the transfer phase the choice accuracy for selecting stimuli with the highest reward probability and avoiding stimuli with the lowest reward probability will be computed.
The effects of treatment will be determined by comparing the accuracy between the losartan- and placebo-treated groups.
|
111 minutes to 120 minutes after treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Benjamin Becker, PhD, University of Electronic Science and Technology of China
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- UESTC-neuSCAN-75
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .